Background and Objective: economic access to medicine and treatment is one of the most important dimensions of the right to health, which is considered one of the goals of national development in addition to international human rights. Achieving this important goal is possible by using correct and specific strategies such as pricing and compensation of costs through insurance.
Methods: First, the literature of the article was reviewed using e-books, and articles, then the qualitative data was analyzed through content analysis and a practical model was presented.
Results: Price control is done in two ways, direct and indirect. Determining the price and correcting it, it is the direct type, and compensation of costs through insurance is considered the indirect type. As the first control step, pricing strategies are followed based on two basic principles: 1- Value-based pricing, which is related to drug effects and drug cost, and includes the same requirements. 2- Price Classification based on the type and nature of the drug, including generic, under patent and imported.
Conclusion: Since Iran has recently abandoned the Cost Plus method (determining the prices based on a percentage more than the total cost), it is necessary to constantly regulated the prices according to the current conditions, needs and the existence of similar drugs, but This action dose not seems correct in any situation and the necessary considerations regarding single-prescription drugs have not been taken into account. While advanced countries such as France and England include all drugs in the insurance coverage list based on their medicinal nature without special requirements and prerequisites, the budget of countries such as Iran does not allow such a thing.